Paul Taylor, M.D., Ph.D., is a scientific co-founder of Faze Medicines, and a pioneer in the field of liquid-liquid phase transitions and how they impact neurodegenerative disease. Dr. Taylor’s research has led to the discovery that some neurodegenerative diseases, including ALS and FTD, are caused by defects in the assembly, disassembly, or clearance of RNA granules. In addition to his work at Faze, Dr. Taylor is an investigator at the Howard Hughes Medical Institute and a faculty chair of the cell and molecular biology department at St. Jude Children’s Research Hospital.
Dr. Taylor was awarded the 2020 Potamkin Prize for his excellent research in neurodegenerative disorders. He received his M.D. and Ph.D. from Jefferson Medical College and completed his clinical training in neurology at the University of Pennsylvania. He completed a neurogenetics fellowship under the mentorship of Kenneth Fischbeck at the National Institutes of Health.